Forte Biosciences (FBRX) filed a registration statement late Tuesday with the US Securities and Exchange Commission for the potential sale of up to $500 million in securities from time to time.
The filing covers common stock, preferred stock, debt securities, depositary shares, warrants, subscription rights, purchase contracts, and units.